DEINOVE benefits from the support of the French government, within the framework of the “France Relance” plan, to accelerate the development of new antimicrobials - Seite 2

From picoliter to 20 liters, the Company is strengthening its position as an industrial biotech dedicated to the identification of “gold nuggets” of natural origin, from the 99.9% unexplored microbial dark matter². With a major gain in yield upstream of the process, Boost-ID will accelerate the development of new antimicrobials and molecules of natural origin with high added value.

Alexis Rideau, CEO of DEINOVE comments: “This support by the French government will accelerate the implementation of our microfluidics platform, with the goal of being operational by the end of 2021. Boost-ID will dramatically increase the platform’s current performance, while reducing its costs, particularly for reagents and plastics. Together with our expertise and technological capabilities in synthetic biology, microfluidics is a turning point in DEINOVE’s history as it will enable us to perform low-cost biological tests at unprecedented rates to explore and exploit microbial dark matter.”

ABOUT DEINOVE

DEINOVE is a French biotechnology company pioneering the exploration of a new domain of life, unexplored at 99.9%: the “microbial dark matter”. By revealing the metabolic potential of rare bacteria or still classified as uncultivable, it tackles a global health and economic challenge: antimicrobial resistance. The new therapies discovered and developed by DEINOVE target superbugs (microbes that have become resistant to one or more antimicrobials) that cause life-threatening infections which are now spreading at high speed.

This breakthrough approach gave rise to one of the world’s first specialized micro-biotechnology platforms and a unique collection of nearly 10,000 rare strains and thousands of bacterial extracts. Today, DEINOVE is conducting several development programs, of which its first antibiotic candidate is currently evaluated in a Phase II clinical trial in severe Clostridioides difficile infections, one of the world’s first emergencies. The Company has also developed new bacterial micro-factories that address the other issue in the race against antimicrobial resistance: the industrial production of these rare and low concentrated compounds with often too complex chemical structures to be generated by chemical synthesis.